The immediate goal of this project is to use functional imaging to define dimensional constructs for reactivity and regulation of potential threat, within the Negative Valence system of the Research Domain Criteria (RDoC). By using these constructs we ground the understanding of anxiety in neural mechanisms, rather than using pre-set diagnostic boundaries, which have inherent assumptions about the structure of anxiety symptoms. In our community, the experience of anxiety is prevalent, and costs $47 billion per year in care and lost time. A wide range of anxiety disorders share common symptoms of anxious arousal, and show hyper- reactivity of the amygdala in functional imaging studies, which we call excessive """"""""Threat reactivity"""""""". Some of these disorders also involve a more generalized loss of adaption accompanied by more cognitive experiences of anxiety, such as apprehensive expectations. They show hypo-activation of the ventral-rostral anterior cingulate, which we call poor """"""""Threat regulation"""""""". Given the commonalities in anxiety phenomena and imaging findings, our goal is to determine whether imaging-defined dimensions of Threat reactivity and regulation provide a primary organizing principle for distinguishing specific features of anxiety and mood symptoms, the behaviors they generate, and their impact on the real world capacity to function socially and at work. To do this we will recruit all people who come through a large community psychology clinic which attends to a broad spectrum of anxiety and mood-related symptoms. These participants will be unmedicated and studied using a coordinated battery of functional imaging, behavioral, self-report and genetic probes, with well established paradigms for threat reactivity and regulation. The immediate aim is to determine if imaging-defined dimensions of amygdala threat reactivity and anterior cingulate threat regulation relate to severity of anxiety symptoms, specifically anxious arousal and apprehensive expectations.
A second aim i s to determine how these dimensions also relate in a cohesive way to behavioral performance in emotional and cognitive domains since, for instance, disruptions to threat processing can temporarily impair cognitive control.
The third aim of the study is to assess how the imaging-defined dimensions affect real world functions related to burden of illness, specifically social functioning, quality of life and work productivity. This will create a personalized medicine approach for the treatment of anxiety disorders that will lead to specific treatments most likely t result in remission of symptoms. Outcomes will result in conceptually valid constructs for understanding what neural mechanisms generate specific experiences of anxiety.

Public Health Relevance

Anxiety is the most prevalent and disabling aspect of poor mental health. It is characterized by a disruption to our normally adaptive responses to threat. Our goal is to advance the innovative understanding of how neural constructs of potential threat defined by functional brain imaging according to Research Domain Criteria (RDoC) are expressed in specific anxiety symptoms and behaviors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH101496-02
Application #
8705033
Study Section
Special Emphasis Panel (ZMH1-ERB-S (04))
Program Officer
Rumsey, Judith M
Project Start
2013-08-01
Project End
2017-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
2
Fiscal Year
2014
Total Cost
$533,823
Indirect Cost
$155,225
Name
Palo Alto Institute
Department
Type
DUNS #
624218814
City
Palo Alto
State
CA
Country
United States
Zip Code
94304
Goldstein-Piekarski, Andrea N; Staveland, Brooke R; Ball, Tali M et al. (2018) Intrinsic functional connectivity predicts remission on antidepressants: a randomized controlled trial to identify clinically applicable imaging biomarkers. Transl Psychiatry 8:57
O'Connell, Chloe P; Goldstein-Piekarski, Andrea N; Nemeroff, Charles B et al. (2018) Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein. Am J Psychiatry 175:251-261
Perry, LeeAnn M; Goldstein-Piekarski, Andrea N; Williams, Leanne M (2017) Sex differences modulating serotonergic polymorphisms implicated in the mechanistic pathways of risk for depression and related disorders. J Neurosci Res 95:737-762
Ball, T M; Goldstein-Piekarski, A N; Gatt, J M et al. (2017) Quantifying person-level brain network functioning to facilitate clinical translation. Transl Psychiatry 7:e1248
Williams, Leanne M (2017) Defining biotypes for depression and anxiety based on large-scale circuit dysfunction: a theoretical review of the evidence and future directions for clinical translation. Depress Anxiety 34:9-24
Goldstein-Piekarski, A N; Williams, L M; Humphreys, K (2016) A trans-diagnostic review of anxiety disorder comorbidity and the impact of multiple exclusion criteria on studying clinical outcomes in anxiety disorders. Transl Psychiatry 6:e847
Williams, Leanne M (2016) Precision psychiatry: a neural circuit taxonomy for depression and anxiety. Lancet Psychiatry 3:472-80
Goldstein-Piekarski, Andrea N; Korgaonkar, Mayuresh S; Green, Erin et al. (2016) Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants. Proc Natl Acad Sci U S A 113:11955-11960
Williams, Leanne M; Goldstein-Piekarski, Andrea N; Chowdhry, Nowreen et al. (2016) Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression (""RAD"") project. BMC Psychiatry 16:68